Ex Vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in niger

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3415-3419

  Issaka, Mariama ^a   Salissou, Adamou ^a   Arzika, Ibrahim ^a   Guillebaud, Julia ^a   Maazou, Abani ^b   Specht, Sabine ^c   Zamanka, Halima ^a   Fandeur, Thierry ^a,d  

^a Centre de Recherche Médicale et Sanitaire   (Nigeria)

^b Programme National de Lutte contre le Paludisme   (Nigeria)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; PIPERAQUINE; PYRONARIDINE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BACTERIUM ISOLATE; CHILD; EX VIVO STUDY; FEMALE; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; NIGER; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; NAPHTHYRIDINES; NIGER; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84879011237     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02383-12     Document Type: Article

References (35)

1. WHO. 2010. World Malaria report. WHO, Geneva, Switzerland. http://www.who.int/malaria/world-malaria-report-2010/worldmalariareport2010.pdf.
2. United Nations Development Programme. 2007. Human development report/2008. Fighting climate change: human solidarity in a divided world. United Nations Development Programme, New York, NY. http://hdr.undp.org/en/ media/HDR-20072008-EN-Complete.pdf.
3. WHO. 2011. World health statistics. WHO, Geneva, Switzerland. http://www.who.int/gho/publications/world-health-statistics/EN-WHS2011-Full.pdf.
4. Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7:864-874.
5. AMFm Task Force. 2007. Affordable medicines facility-malaria (AMFm). Roll Back Malaria Partnership, Geneva, Switzerland. http://www.rollbackmalaria.org/ partnership/tf/globalsubsidy/AMFmTechProposal.pdf.
6. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
7. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718. (Pubitemid 10082023)
8. Lim P, Chim P, Sem R, Nemh S, Poravuth Y, Lim C, Seila S, Tsuyuoka R, Denis MB, Socheat D, Fandeur T. 2005. In vitro monitoring of Plasmodium falciparum susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001-2002. Acta Trop. 93:31-40. (Pubitemid 39611352)
9. Basco LK, Bickii J, Ringwald P. 1998. In vitro activity of lumefantrine (Benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob. Agents Chemother. 42:2347-2351. (Pubitemid 28420376)
10. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Amalvict R, Gardair JP, Rogier C. 2006. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J. Clin. Microbiol. 44:2404-2408. (Pubitemid 44092404)
11. Basco LK, Le Bras J. 1993. In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 49:301-307. (Pubitemid 23289387)
12. Basco LK, Ringwald P. 2003. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47:1391-1394. (Pubitemid 36368602)
13. Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugère B, Ménard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, Pradines B. 2012. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar. J. 11:45. doi:10.1186/1475-2875-11-45.
14. Briolant S, Henry M, Oeuvray C, Amalvict R, Baret RE, Didillon E, Rogier C, Pradines B. 2010. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob. Agents Chemother. 54:3537-3544.
15. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. 2010. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob. Agents Chemother. 54:1200-1206.
16. Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Wade B, Bercion R, Pradines B. 2011. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar. J. 10:310. doi:10.1186/1475-2875-10-310.
17. Kremsner PG, Taylor T, Issifou S, Kombila M, Chimalizeni Y, Kawaza K, Bouyou Akotet MK, Duscha M, Mordmüller B, Kösters K, Humberg A, Miller RS, Weina P, Duparc S, Möhrle J, Kun JF, Planche T, Teja-Isavadharm P, Simpson JA, Köhler C, Krishna S. 2012. A simplified intravenous artesunate regimen for severe malaria. J. Infect. Dis. 205:312-319.
18. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A. 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53:5069-5073.
19. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:1960-1966.
20. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. N. Engl. J. Med. 365:1073-1075.
21. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O. 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type Pf AT Pase6. Lancet 366:1960-1963. (Pubitemid 41713986)
22. Ibrahim ML, Steenkeste N, Khim N, Adam HH, Konaté L, Coppée JY, Ariey F, Duchemin JB. 2009. Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA microarrays and PCR/RFLP in Niger. Malar. J. 8:32. doi:10.1186/1475-2875-8-32.
23. WHO. 2000. Global report on antimalarial efficacy and drug resistance: 2010. WHO, Geneva, Switzerland. whqlibdoc.who.int/publications/2010/ 9789241500470-eng.pdf.
24. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ. 2009. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J. Infect. Dis. 200: 1650-1657.
25. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P. 2004. Lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am. J. Trop. Med. Hyg. 713:294-296. (Pubitemid 39223505)
26. Folarin OA, Bustamante C, Gbotosho GO, Sowunmi A, Zalis MG, Oduola AM, Happi CT. 2011. In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. Acta Trop. 120:224-230.
27. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191:1014-1017. (Pubitemid 40349821)
28. Nosten F, White NJ. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77:181-192.
29. Parola P, Ali I, Djermakoye F, Crassard N, Bendavid C, Faugère B, Condomines P. 1999. Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger). Bull. Soc. Pathol. Exot. 92:317-319. (In French.)
30. Dugelay F, Adehossi E, Adamou S, Ousmane I, Parzy D, Delmont J, Parola P. 2003. Efficacy of chloroquine in the treatment of uncomplicated, Plasmodium falciparum malaria in Niamey, Niger, in 2001. Ann. Trop. Med. Parasitol. 97:83-86. (Pubitemid 36279019)
31. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein Pf CRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871.
32. Ibrahim ML, Gay-Andrieu F, Adehossi E, Lacroix V, Randrianarivelojosia M, Duchemin JB. 2007. Field-based evidence for the linkage of pfcrt and pfdhfr drug-resistant malaria genotypes and clinical profiles of severe malaria in Niger. Microbes Infect. 9:599-604. (Pubitemid 46602032)
33. Ariey F, Robert V. 2003. The puzzling links between malaria transmission and drug resistance. Trends Parasitol. 19:158-160. (Pubitemid 36411969)
34. Doudou MH, Mahamadou A, Ouba I, Lazoumar R, Boubacar B, Arzika I, Zamanka H, Ibrahim ML, Labbo R, Maiguizo S, Girond F, Guillebaud J, Maazou A, Fandeur T. 2012. A refined estimate of the malaria burden in Niger. Malar. J. 11:89. doi:10.1186/1475-2875-11-89.
35. Maxmen A. 2012. Malaria plan under scrutiny. Nature 490:13-14.